Elsevier

Clinical Biochemistry

Volume 37, Issue 7, July 2004, Pages 549-561
Clinical Biochemistry

Review
Human chorionic gonadotropin in cancer

https://doi.org/10.1016/j.clinbiochem.2004.05.008Get rights and content

Abstract

Human chorionic gonadotropin (hCG) is mainly used for detection and monitoring of pregnancy and pregnancy-related disorders but it is also an extremely sensitive and specific marker for trophoblastic tumors of placental and germ cell origin. Thus treatment of relapsing choriocarcinomas and testicular germ cell tumors is often initiated on the basis of rising hCG levels even in the absence of clinical or histological evidence of a relapse. While these tumors mostly produce the intact heterodimeric hormone consisting of an α (hCGα), and a β subunit (hCGβ), many nontrophoblastic tumors produce only hCGβ This is usually a sign of aggressive disease and elevated serum levels of hCGβ are strongly associated with poor prognosis. Elevated serum levels are observed in 45–60% of patients with biliary and pancreatic cancer and in 10–30% of most other cancers. Methods that detect hCG and hCGβ together are mainly used for measurement of hCG-like immunoreactivity in serum. However, the reference range for hCG is 5–8 fold higher than that for hCGβ and thus moderately elevated levels can be identified only with a specific and sensitive hCGβ assay.

Introduction

Human chorionic gonadotropin (hCG) is a glycoprotein hormone produced at very high concentrations by placental trophoblasts. During pregnancy, the serum concentrations increase rapidly peaking at 7–10 weeks. Placental and other trophoblastic tumors virtually always express hCG, and for these hCG is a very sensitive marker. In addition, serum from many patients with nontrophoblastic tumors contains hCG-immunoreactivity, which with few exceptions consists of the free β subunit of hCG (hCGβ), but expression of intact hCG occasionally occurs in various tumors. Elevated expression of hCGβ in serum, urine, or tumor tissue is a strong indicator of adverse prognosis in many nontrophoblastic tumors. However, hCG and hCGβ are also expressed at low levels by many normal tissues. By using sensitive and specific assays, both hCG and hCGβ can be detected at low concentrations in serum and urine from most men and nonpregnant women. This review will describe the use of various forms of hCG for diagnosis of cancer with emphasis on recent developments in the field.

hCG belongs to the glycoprotein hormone family that also comprises luteinizing hormone (LH), follicle-stimulating hormone (FSH), and thyroid-stimulating hormone (TSH). All members are heterodimers consisting of an α and β subunit. The α subunit, which is common to all glycoprotein hormones, contains 92 amino acids. The β chains determine the biological activity and display extensive homology, that between hCGβ and LHβ  being about 80%. LHβ contains 121 and hCGβ 145 amino acids, the difference coming from a 24 amino acid C-terminal extension. The molecular weight of hCG is about 37,500, that of hCGβ is 23,500 and that of hCGα is 14,000 [1], [2]. About one-third of the molecular weight of hCG consists of carbohydrates attached to six glycosylation sites on hCGβ and two on hCGα. The N-linked carbohydrate chains on hCGα are attached to Asn52 and Asn78 and two on hCGβ to Asn13 and Asn30. Four O-linked carbohydrate chains on the C-terminal peptide (CTP) of hCGβ are attached to Ser121, Ser127, Ser132, and Ser138. The carbohydrate chains contain 8–15 terminal sialic acids, and therefore hCG displays extensive charge heterogeneity. In isoelectric focusing, hCG can be separated into components with isoelectric points (pI) between 3 and 7. hCGβ displays pI values in the range 3–5 and hCGα pI values in the range 5–8 [2], [3]. In pregnancy, most of the N-linked carbohydrates on hCGα are mono- and biantennary, and those on hCGβ biantennary and to a lesser extent triantennary. More complex carbohydrates are found in so-called hyperglycosylated hCG produced by choriocarcinoma; triantennary N-linked carbohydrates are common on hCGβ and the O-linked carbohydrates have a biantennary type 2 o-core structure rather than the monoantennary type 1 core in pregnancy hCG. However, in early pregnancy, a large proportion of hCG is also hyperglycosylated [4]. In addition to carbohydrate and charge variants, free subunits and partially degraded forms of hCG occur not only in urine but also in serum of cancer patients [5], [6], [7].

When excreted into urine, much of hCG and hCGβ is degraded to partially cleaved or “nicked“ forms and fragments. In nicked hCG (hCGn) and hCGβ (hCGβn), the peptide chain is cleaved between amino acids 44–45 and 47–48. Much of the hCG-immunoreactivity in urine consists of a fragment of hCGβ [8], [9] comprising amino acids 6–40 and 55–92 linked together by disulfide bridges [7]. This fragment is called the core fragment of hCGβ (hCGβcf) [10]. Methods measuring hCGβcf may also measure other degraded forms of hCG, which collectively have been called urinary gonadotropin fragments (UGF) [11] and urinary gonadotropin peptide (UGP) [12]. Different degraded forms are recognized to a variable extent by different antibodies [13] causing between-assay-variation especially when determining hCG in urine. This is of importance mainly for pregnancy tests [14] because serum assays are used for monitoring of hCG during pregnancy and in cancer patients.

HCGα is encoded by a single gene on chromosome 12q21.1-23 and hCGβ by six nonallelic genes clustered on 19q13.3 together with the gene encoding LHβ. The genes are designated CGβ1-CGβ9. Of these, two pseudogenes, β1 and β2, are not expressed while β4 encodes LH. Of the expressed hCG genes, β7 and β9 are alleles to β6 and β3, respectively. Two structurally different forms of hCG are expressed, genes β6/7, which are called type I genes, encode a protein with alanine at position 117 while type II genes β3/9, β5, and β8 encode a protein with aspartic acid at this position. The expression of type I and II genes is tissue-dependent. Type II genes are predominantly expressed by the placenta, malignant tumors, and testis, while type I genes are preferentially expressed at very low levels by normal nontrophoblastic tissues [15].

LH and hCG mediate their activity through the same receptor. During pregnancy, hCG stimulates steroid hormone production in the ovaries. In early pregnancy, hCG production starts around the time of implantation of the fetus, and elevated serum levels can be detected about 7 days after the LH surge, which is followed by ovulation within 36–48 h. The amount of trophoblast tissue needed to produce detectable concentrations of hCG in serum is extremely low. A trophoblastic tumor containing only 10,000 cells can cause an increase in serum hCG [16].

The subunits lack hCG activity, but hCGβ has been shown to enhance the growth of tumor cells in culture by preventing apoptosis [17]. While this finding needs to be confirmed, it could explain why expression of hCGβ is associated with aggressive cancer.

Section snippets

Standards

Standards issued by WHO are used to calibrate immunoassays for hCG and its subunits. The presently used 3rd (and the identical 4th) international standard (3rd IS) for hCG was assigned values in international units (IU) by comparing its bioactivity to that of the earlier 2nd standard. Because the free subunits lack hCG activity, they were assigned values based on mass, 1 μg corresponding to 1 IU. One microgram of hCG corresponds to 9.3 IU, thus the units for hCG and its subunits are not

Gestational trophoblastic disease

Gestational trophoblastic disease comprises a spectrum of diseases with different propensity for local invasion and metastasis, that is, partial and complete hydatidiform mole, choriocarcinoma, and placental site trophoblastic tumor (PSTT). Persistent trophoblastic disease may develop both from partial and complete moles. All trophoblastic tumors produce hCG, and monitoring of therapy is largely based on the determination of hCG in serum [52]. The more malignant forms also express excessive

HCG in nontrophoblastic cancer

Expression of hCG-immunoreactivity is observed in a variable proportion of many nontrophoblastic tumors. This immunoreactivity mainly consists of hCGβ while hCG expression is rare [37], [39]. However, the first description of a gonadotropin-producing nontrophoblastic tumor was a hepatoblastoma causing precocious puberty in a 2-year-old boy [89]. This is a very rare condition with only 25 cases having been reported by 1985 [90]. Most cases of precocious puberty are idiopathic, one-fifth of those

Detection of tumor cells in blood and urine by RT-PCR of hCGβ mRNA

Determination of hCGβ mRNA in peripheral blood has successfully been used to detect tumor cells in circulation from patients with chorionic cancer [169] and, together with AFP mRNA, in germ cell tumors [169]. Germ cell cancer patients with poor prognosis or relapsed metastatic disease are increasingly treated with high-dose chemotherapy followed by autologous peripheral-blood stem-cell (PBSC) transplantation, and determination of hCGβ and other tumor-associated genes in the PBSC products by

Conclusions

Determination of hCG plays a crucial role in the management of placental trophoblastic disease as well as in testicular tumors. Expression of hCGβ is common in nontrophoblastic cancers and, together with other markers, hCGβ in serum and hCGβcf in urine can be used to improve the diagnostic accuracy for some tumors. At the moment, this use is limited by lack of sensitive commercial assays. Expression of hCGβ is associated with adverse prognosis, and detection of this expression may become

References (173)

  • M.B. Khazaeli et al.

    Radioimmunoassay of the free β-subunit of human chorionic gonadotropin in diagnosis of high-risk and low-risk gestational trophoblastic disease

    Am. J. Obstet. Gynecol.

    (1989)
  • J. Vartiainen et al.

    Identification of choriocarcinoma by the hCG beta-to-hCG proportion in patients with delayed diagnosis caused by contraceptive use

    Contraception

    (1998)
  • S. Birken et al.

    Immunochemical measurement of early pregnancy isoforms of HCG: potential applications to fertility research, prenatal diagnosis, and cancer

    Arch. Med. Res.

    (2001)
  • C.M. Feltmate et al.

    Human chorionic gonadotropin follow-up in patients with molar pregnancy: a time for reevaluation

    Obstet. Gynecol.

    (2003)
  • K.A. Yedema et al.

    Identification of patients with persistent trophoblastic disease by means of a normal human chorionic gonadotropin regression curve

    Am. J. Obstet. Gynecol.

    (1993)
  • J.I. Mayordomo et al.

    Ovarian and extragonadal malignant germ-cell tumors in females: a single-institution experience with 43 patients

    Ann. Oncol.

    (1994)
  • Y. Zalel et al.

    Diagnosis and management of malignant germ cell ovarian tumors in young females

    Int. J. Gynaecol. Obstet.

    (1996)
  • P.H. Lange et al.

    Marker half-life analysis as a prognostic tool in testicular cancer

    J. Urol.

    (1982)
  • C.L. Coogan et al.

    Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone

    Urology

    (1997)
  • O. Klepp et al.

    Risk-adapted treatment of clinical stage 1 non-seminoma testis cancer

    Eur. J. Cancer

    (1997)
  • J.R. Tsai et al.

    Use of urine pregnancy test for rapid diagnosis of primary pulmonary choriocarcinoma in a man

    Chest

    (2002)
  • J.G. Pierce et al.

    Glycoprotein hormones: structure and function

    Annu. Rev. Biochem.

    (1981)
  • S. Birken et al.

    Preparation and characterization of new WHO reference reagents for human chorionic gonadotropin and metabolites

    Clin. Chem.

    (2003)
  • G. Kovalevskaya et al.

    Differential expression of human chorionic gonadotropin (hCG) glycosylation isoforms in failing and continuing pregnancies: preliminary characterization of the hyperglycosylated hCG epitope

    J. Endocrinol.

    (2002)
  • H.R. Masure et al.

    Characterization of a small molecular size urinary immunoreactive human chorionic gonadotropin (hCG)-like substance produced by normal placenta and by hCG-secreting neoplasms

    J. Clin. Endocrinol. Metab.

    (1981)
  • L.A. Cole et al.

    Absence of the COOH-terminal peptide on ectopic human chorionic gonadotropin beta-subunit (hCG beta)

    Endocrinology

    (1982)
  • S. Birken et al.

    Structure of the human chorionic gonadotropin beta-subunit fragment from pregnancy urine

    Endocrinology

    (1988)
  • D.L. Matthies et al.

    Relationships between physico-chemical, immunological and biological properties of human chorionic gonadotrophin. I. Properties of human chorionic gonadotrophin as found in tissues and body fluids

    Acta Endocrinol. (Copenh.)

    (1971)
  • P.D. Papapetrou et al.

    Ectopic production of human chorionic gonadotropin (hCG) by neoplasms: the value of measurements of immunoreactive hCG in the urine as a screening procedure

    Cancer

    (1980)
  • U.-H. Stenman et al.

    Standardization of protein immunoprocedures. Choriogonadotropin (CG)

    Scand. J. Clin. Lab. Invest., Suppl.

    (1993)
  • L.A. Cole et al.

    Urinary human chorionic gonadotropin free beta-subunit and beta-core fragment: a new marker of gynecological cancers

    Cancer Res.

    (1988)
  • P.E. Schwartz et al.

    Clinical applications of urinary gonadotropin peptides (UGP) in gynecologic oncology

    Anticancer Res.

    (1996)
  • J.F. O'Connor et al.

    Development of highly sensitive immunoassays to measure human chorionic gonadotropin, its beta-subunit, and beta core fragment in the urine: application to malignancies

    Cancer Res.

    (1988)
  • D. Bellet et al.

    Malignant transformation of nontrophoblastic cells is associated with the expression of chorionic gonadotropin beta genes normally transcribed in trophoblastic cells

    Cancer Res.

    (1997)
  • K. Mann et al.

    Clinical use of HCG and hCG beta determinations

    Scand. J. Clin. Lab. Invest., Suppl.

    (1993)
  • S.A. Butler et al.

    The increase in bladder carcinoma cell population induced by the free beta subunit of human chorionic gonadotrophin is a result of an anti-apoptosis effect and not cell proliferation

    Br. J. Cancer

    (2000)
  • C. Lottersberger et al.

    Tumor- and pregnancy-derived isoforms of human chorionic gonadotropin: biological and diagnostic relevance

    Horm. Res.

    (2003)
  • W.D. Odell et al.

    Radioimmunoassay for luteinizing hormone in human plasma and serum: physiological studies

    J. Clin. Invest.

    (1967)
  • R.O. Hussa

    The clinical marker hCG

    (1987)
  • J.M. Bidart et al.

    Identification of epitopes associated with hCG and the beta hCG carboxyl terminus by monoclonal antibodies produced against a synthetic peptide

    J. Immunol.

    (1985)
  • P.H. Ehrlich et al.

    Characterization and relative orientation of epitopes for monoclonal antibodies and antisera to human chorionic gonadotropin

    Am. J. Reprod. Immunol. Microbiol.

    (1985)
  • R.J. Norman et al.

    Monoclonal antibodies to human chorionic gonadotropin: implications for antigenic mapping, immunoradiometric assays, and clinical applications

    J. Clin. Endocrinol. Metab.

    (1985)
  • S. Schwarz et al.

    Epitope-selective, monoclonal-antibody-based immunoradiometric assays of predictable specificity for differential measurement of choriogonadotropin and its subunits

    Clin. Chem.

    (1985)
  • H. Alfthan et al.

    Concentrations of human chorionic gonadotropin, its β-subunit and the core fragment of the β-subunit in serum and urine of men and nonpregnant women

    Clin. Chem.

    (1992)
  • R. Hoermann et al.

    Immunological recognition and clinical significance of nicked human chorionic gonadotropin in testicular cancer

    Clin. Chem.

    (1994)
  • P. Berger et al.

    The ISOBM TD-7 workshop on hCG and related molecules. Towards user-oriented standardization of pregnancy and tumor diagnosis: assignment of epitopes to the three-dimensional structure of diagnostically and commercially relevant monoclonal antibodies directed against human chorionic gonadotropin and derivatives

    Tumour Biol.

    (2002)
  • M.M. Elliott et al.

    Carbohydrate and peptide structure of the alpha- and beta-subunits of human chorionic gonadotropin from normal and aberrant pregnancy and choriocarcinoma

    Endocrine

    (1997)
  • S. Birken et al.

    Development and characterization of antibodies to a nicked and hyperglycosylated form of hCG from a choriocarcinoma patient: generation of antibodies that differentiate between pregnancy hCG and choriocarcinoma hCG

    Endocrine

    (1999)
  • L.A. Cole

    Immunoassay of human chorionic gonadotropin, its free subunits, and metabolites

    Clin. Chem.

    (1997)
  • K. Pettersson et al.

    Time-resolved fluoroimmunoassay of human choriogonadotropin

    Clin. Chem.

    (1983)
  • Cited by (235)

    View all citing articles on Scopus
    View full text